Astellas Pharma (OTCMKTS:ALPMY) Shares Cross Above 50-Day Moving Average – Time to Sell?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $14.02 and traded as high as $16.71. Astellas Pharma shares last traded at $16.06, with a volume of 141,401 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, Astellas Pharma currently has an average rating of “Hold”.

Astellas Pharma Stock Down 3.0%

The company has a fifty day moving average price of $14.02 and a two-hundred day moving average price of $12.22. The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.29 by $0.15. Astellas Pharma had a net margin of 15.63% and a return on equity of 24.24%. The firm had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.21 billion. Equities analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).